Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

4Q Pharma Results Preview: J&J, Novartis, Bristol, Celgene, Biogen

Executive Summary

Scrip offers some key points to watch for as Johnson & Johnson and Novartis kick off the big pharma full-year presentations Jan. 24, with Bristol-Myers Squibb, Celgene and Biogen Idec finishing off the first week of earnings season.

Advertisement

Related Content

Patent Settlement Offers Some Salve For Bristol’s PD-1 Wounds
Game Changer: Merck's Stealth Keytruda-Chemo Filing Stirs NSCLC Market Dynamics
Pharma Strategizes On Drug Pricing On Day One Of J.P. Morgan
Biogen/Ionis’s Spinraza Approved; Second Antisense Drug For Neurodegeneration In 2016
Was Sanofi’s Offer One That Actelion Could Refuse? J&J Back At Bargaining Table
Actelion Could Succumb To Big Pharma's Charms
Novartis Chief: Good Things Come To Those Who Wait
'Total Disaster' In First-Line Lung Cancer For BMS's Opdivo
Celgene diversifies with $7.2bn Receptos buy

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC098049

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel